EC grants approval for AbbVie’s Skyrizi to treat Crohn’s disease

Title: EC Approves AbbVie’s Skyrizi as a Breakthrough Treatment for Crohn’s Disease


In a significant development for the treatment of Crohn’s disease, the European Commission (EC) has granted approval to AbbVie’s Skyrizi. This breakthrough therapy offers renewed hope to patients living with Crohn’s disease, providing an effective and innovative treatment option. In this blog, we will explore the key points surrounding the EC’s approval of Skyrizi and its potential impact on the management of Crohn’s disease.

Key Points:

  1. Understanding Crohn’s Disease:
    • Crohn’s disease is a chronic inflammatory bowel disease that causes inflammation in the digestive tract.
    • It can result in a range of symptoms, including abdominal pain, diarrhea, fatigue, and weight loss.
  2. Introduction to Skyrizi:
    • Skyrizi is a groundbreaking therapy developed by AbbVie that has previously gained approval for treating psoriasis and psoriatic arthritis.
    • Now, with EC approval, Skyrizi can be prescribed as a treatment for Crohn’s disease.
  3. Significance of EC Approval:
    • The approval of Skyrizi by the EC signifies its effectiveness and safety in treating Crohn’s disease, based on rigorous clinical trials and scientific evidence.
    • This recognition demonstrates a crucial step forward in addressing the unmet needs of patients with Crohn’s disease.
  4. Mechanism of Action:
    • Skyrizi, also known as risankizumab, works by targeting and inhibiting the interleukin-23 (IL-23) pathway, a key driver of inflammation in Crohn’s disease.
    • By blocking IL-23, Skyrizi helps reduce the inflammation associated with Crohn’s disease, providing relief for patients.
  5. Efficacy in Clinical Trials:
    • The efficacy of Skyrizi in treating Crohn’s disease has been demonstrated through robust clinical trials.
    • Patients receiving Skyrizi showcased significant improvements in symptoms, reduced inflammation, and increased rates of clinical remission compared to the control group.
  6. Safety Profile:
    • Skyrizi‘s safety profile has been thoroughly evaluated during clinical trials.
    • Common side effects observed were consistent with the known risks associated with immunosuppressive medications, and no new safety concerns surfaced.
  7. Targeted Therapy for Crohn’s Disease:
    • Skyrizi’s approval as a targeted therapy addresses the need for more personalized treatment options in Crohn’s disease.
    • By specifically inhibiting IL-23, Skyrizi offers a targeted approach that can minimize potential side effects associated with broader immunosuppressive therapies.
  8. Improving Quality of Life:
    • The introduction of Skyrizi as a treatment option for Crohn’s disease holds the promise of improving the quality of life for patients.
    • By reducing symptoms, inflammation, and promoting remission, Skyrizi allows patients to better manage their condition and experience an enhanced overall well-being.
  9. Future Implications:
    • The approval of Skyrizi for Crohn’s disease represents a significant step forward in the treatment landscape for this challenging condition.
    • It sets a precedent for other targeted therapies and encourages further research and development in the field of inflammatory bowel diseases.


The EC’s approval of AbbVie’s Skyrizi as a breakthrough treatment for Crohn’s disease marks a significant milestone in the management of this complex condition. Skyrizi’s targeted approach to inhibiting IL-23 offers new hope for patients, providing effective symptom relief, reducing inflammation, and promoting clinical remission. This approval not only highlights the potential of targeted therapies in addressing the unmet needs of patients but also paves the way for further advancements in the treatment of inflammatory bowel diseases. With Skyrizi’s introduction, patients living with Crohn’s disease can look forward to an improved quality of life and more personalized treatment options in their journey towards better health.